Help ?

IGMIN: あなたがここにいてくれて嬉しいです. お願いクリック '新しいクエリを作成してください' 当ウェブサイトへの初めてのご訪問で、さらに情報が必要な場合は.

すでに私たちのネットワークのメンバーで、すでに提出した質問に関する進展を追跡する必要がある場合は, クリック '私のクエリに連れて行ってください.'

Subjects Content

Welcome to IgMin Research – an Open Access journal uniting Biology Group, Medicine Group, and Engineering Group. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.

Biology Group

The Biology Group explores diverse topics in life sciences, providing open access to cutting-edge research and fostering global collaboration in biological studies.

Medicine Group

The Medicine Group focuses on advancing medical knowledge through open access research, promoting innovation, and encouraging global collaboration in healthcare studies.

Engineering Group

The Engineering Group showcases cutting-edge research across engineering fields, providing open access and encouraging global collaboration and innovation.

General Science Group

The General Science Group covers a broad range of scientific disciplines, offering open access to research that drives innovation and fosters global collaboration.

Members Content

We are dedicated to creating intersections where disciplines meet to expand knowledge.

Articles Content

We are dedicated to creating intersections where disciplines meet to expand knowledge.

Identify Us

We are dedicated to creating intersections where disciplines meet to expand knowledge.

IgMin Corporation

Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.

Publications Support
publications.support@igmin.org
E-Books Support
ebooks.support@igmin.org
Webinars & Conferences Support
webinarsandconference@igmin.org
Content Writing Support
contentwriting.support@igmin.org

Search

Explore Section

Content for the explore section slider goes here.

Abstract

要約 at IgMin Research

We are dedicated to creating intersections where disciplines meet to expand knowledge.

Medicine Group Case Report 記事ID: igmin228

Levetiracetam-induced Rhabdomyolysis - A Rare Complication

Neurology Affiliation

Affiliation

    Section of Neurology, Department of Medicine, Aga Khan University, National Stadium Road, Karachi, Pakistan

要約

Background: Levetiracetam is an anti-epileptic drug that works by modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein 2A. Levetiracetam is generally well tolerated. Common side effects of levetiracetam include lethargy, drowsiness, headaches, and mood changes. Rhabdomyolysis and an increase in Creatine Kinase (CK) levels are one of the rarely reported effects of levetiracetam.
Case presentation: We present a case of a 20-year-old patient with previously known epilepsy (non-compliant with medicine) who presented with a seizure. The patient was given 1 gram of levetiracetam in the emergency department and was kept at a maintenance dose of 500 mg twice a day. The workup revealed acute kidney injury and raised levels of creatinine kinase that peaked at 19,757 IU/L 72 hours after levetiracetam was started. Levetiracetam was later switched to lamotrigine and aggressive intravenous hydration was done. Gradual improvement of CK level was noted accompanied by improvement in renal function.
Conclusion: Only a few cases of levetiracetam-induced rhabdomyolysis have been reported worldwide. Our case report highlights the importance of monitoring creatinine and CK levels while treating patients with levetiracetam as rhabdomyolysis can be asymptomatic with a rise in CK levels only.

数字

参考文献

    1. Moinuddin IA. Suspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review. Am J Case Rep. 2020 Oct 28;21:e926064. doi: 10.12659/AJCR.926064. PMID: 33112844; PMCID: PMC7603803.
    2. Tiglis M, Hurmuzache T, Bologa C, Neagu TP, Mirea L, Grintescu IM. Rhabdomyolysis-Induced Acute Renal Injury in a Schizophrenic Patient. J Crit Care Med (Targu Mures). 2020 Nov 7;6(4):249-252. doi: 10.2478/jccm-2020-0032. PMID: 33200097; PMCID: PMC7648442.
    3. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009 Jul 2;361(1):62-72. doi: 10.1056/NEJMra0801327. Erratum in: N Engl J Med. 2011 May 19;364(20):1982. PMID: 19571284.
    4. Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015 Spring;15(1):58-69. PMID: 25829882; PMCID: PMC4365849.
    5. Shahbaz N, Younus SM, Khan SA, Ain Q-, Khan MA, Memon MH. Levetiracetam Induced Increase in Creatine Phosphokinase Levels. J Coll Physicians Surg Pak. 2017 Mar;27(3):S63-S64. PMID: 28302251.
    6. Akiyama H, Haga Y, Sasaki N, Yanagisawa T, Hasegawa Y. A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy Behav Case Rep. 2014 Sep 16;2:152-155. doi: 10.1016/j.ebcr.2014.08.001. PMID: 25667895; PMCID: PMC4308062.
    7. Al-Quliti K, Alhujeily RM. Acute kidney injury with levetiracetam in patient with epilepsy: a case report. Case Reports in Clinical Medicine. 2022;11(3):48-54.
    8. Di Lorenzo R, Li Y. Rhabdomyolysis associated with levetiracetam administration. Muscle Nerve. 2017 Jul;56(1):E1-E2. doi: 10.1002/mus.25548. Epub 2017 Mar 23. PMID: 28039868.
    9. Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008 Jun;4(3):507-523. doi: 10.2147/ndt.s2937. PMID: 18830435; PMCID: PMC2526377.
    10. Carnovale C, Gentili M, Antoniazzi S, Clementi E, Radice S. Levetiracetam-induced rhabdomyolysis: Analysis of reports from the Food and Drug Administration's Adverse Event Reporting System database. Muscle Nerve. 2017 Dec;56(6):E176-E178. doi: 10.1002/mus.25972. Epub 2017 Sep 30. PMID: 28888059.
    11. Kim H, Jo S, Park KW, Han SH, Lee SA. A Case of Phenytoin-induced Rhabdomyolysis in Status Epilepticus. J Epilepsy Res. 2016 Jun 30;6(1):36-38. doi: 10.14581/jer.16007. PMID: 27390679; PMCID: PMC4933680.
    12. Prendergast BD, George CF. Drug-induced rhabdomyolysis--mechanisms and management. Postgrad Med J. 1993 May;69(811):333-336. doi: 10.1136/pgmj.69.811.333. PMID: 8393995; PMCID: PMC2399808.
    13. Gunathilake R, Boyce LE, Knight AT. Pregabalin-associated rhabdomyolysis. Med J Aust. 2013;199(9):624-625.
    14. Kazmi JS, Albarghouthy N, Ramsaywak R. Levetiracetam-Induced Rhabdomyolysis Reversed by Discontinuation: A Case Report. Cureus. 2023;15(11):e48955. doi: 10.7759/cureus.48955. PMID: 38111426; PMCID: PMC10726084.
    15. Nizamudeen K, Sabu ST, Dharan SS. An overview of the rare and life-threatening adverse effects of levetiracetam. World Journal of Pharmaceutical Research. 9:649-670. DOI: 10.20959/wjpr202011-18761

類似の記事

The Educational Role of Cinema in Physical Sciences
Maria Sagri, Denis Vavougios and Filippos Sofos
DOI10.61927/igmin121
Examining the Causal Connection between Lipid-lowering Medications and Malignant Meningiomas through Drug-target Mendelian Randomization Analysis
Liantai Song, Xiaoyan Guo, Wenhui Zhang, Mengjie Li, Xinyi Wu, Ziqian Kou, Yuxin Wang, Zigeng Ren and Qian Xu
DOI10.61927/igmin187
Solar Energy Resource Potentials of the City of Arkadag
Penjiyev Ahmet Myradovich and Orazov Parahat Orazmuhamedovich
DOI10.61927/igmin119

ソーシャルアイコン

研究を公開する

私たちは、科学、技術、工学、医学に関する幅広い種類の記事を編集上の偏見なく公開しています。

提出する

見る 原稿のガイドライン 追加 論文処理料

IgMin 科目を探索する
グーグルスカラー
welcome Image

Google Scholarは2004年11月にベータ版が発表され、幅広い学術領域を航海する学術ナビゲーターとして機能します。それは査読付きジャーナル、書籍、会議論文、論文、博士論文、プレプリント、要約、技術報告書、裁判所の意見、特許をカバーしています。 IgMin の記事を検索